Do you have any questions? (088) 2080369 - 2345622 Pharmacy_QAAU@pharm.aun.edu.eg
Announcement of coursework grades for the " Phytochemistry -1" course – Semester (5) for the Clinical Pharmacy program for the academic year 2025/2026
Announcement of Results and Appeals for Midterm Exam Grades for " Pharmacognosy 2" - Second Year Pharmacy Students, Private University, Academic Year 2025/2026
Click
?
Students wishing to appeal their midterm exam grade should register their names with the department secretary starting Tuesday, November 25, 2025.
The results of the appeals will be announced for students who have registered with the department secretary.
news category
إعلانات الطلاب
Announcement of Results and Request for Continuous Assessment Marks for the medicinal plants course – First-Year Pharm D, National University, Academic Year 2025/2026
Announcement of Results and Request for Continuous Assessment Marks for the applied and forensic pharmacognosy course – Fourth-Year Pharm D, Academic Year 2025/2026
Congratulations on the Selection of a Distinguished Group of Professors and Associate Professors as Reviewers for Evaluating Scientific Output for the 15th Cycle (2025–2028).
Congratulations on the appointment of Prof. Dr. Noha Nahedj Atia Mohamed - as Vice Dean for Community Service and Environmental Development Affairs
The Family of the Faculty of Pharmacy – Assiut University
extends its sincere congratulations to
Prof. Dr. Noha Nahedj Atia Mohamed,
Professor in the Department of Pharmaceutical Analytical Chemistry,
on the occasion of her appointment as
Vice Dean for Community Service and Environmental Development Affairs at the Faculty of Pharmacy.
Wishing her all the best and continued success.،،،
news category
خبر عام
Congratulations on the appointment of Prof. Dr. Yaser Ghallab Gouda Hussein as Chairman of the Department of Pharmacognosy
The Family of the Faculty of Pharmacy – Assiut University
extends its sincere congratulations to
Prof. Dr. Yaser Ghallab Gouda Hussein,
Professor in the Department of Pharmacognosy,
on the occasion of his appointment as
Chairman of the Department of Pharmacognosy at the Faculty of Pharmacy.
Wishing him all the best and continued success.،،،
news category
خبر عام
Neuroprotective Effect of Empagliflozin/Rivastigmine in Alzheimer's Disease Rat Model: Optimization of Multifaceted Mechanism of Action
Research Abstract
This study assessed the neuroprotective potential of empagliflozin (EMPA) as antidiabetic drug on glucose metabolism,
comparing it to rivastigmine (RIVA) as standard treatment for Alzheimer's disease (AD), and their combination. Male rats were
sorted into five groups. Group I served as the control, while groups II, III, IV, and V received the scopolamine plus heavy metal
mixture for AD induction. Groups III and IV were administered RIVA and EMPA, respectively, and group V received both
treatments. Cognitive function was evaluated behaviorally. Subsequently, glucose levels, acetylcholinesterase, oxidative stress,
and inflammatory markers were assessed. Alongside the brain histopathological changes, the expression of phosphorylated tau
protein was assessed. Moreover, glycolytic enzymes and glucose transporters were assessed using PCR analysis. The findings
were attributed to a notable suppressive impact of EMPA on lipid peroxidation, acetylcholinesterase, glucose levels, phos
phorylated tau protein, pro‐inflammatory cytokines, and neuropathological changes, while enhancing antioxidant and
interleukin‐10 levels. It also improves glucose metabolism. The findings suggest that EMPA may be a viable candidate for future
therapeutic exploration in AD, which has a multifaceted mechanism of action encompassing anti‐neuroinflammation, anti
oxidant stress, and enhanced glucose metabolism, as well as decreased acetylcholinesterase activity and phosphorylated tau
protein levels. Interestingly, combined treatment showed a superior effect than EMPA alone.
Research Date
Research Department
Research Journal
Drug Development Research
Research Member
Research Publisher
Wiley
Research Rank
Q1
Research Vol
86
Research Website
https://doi.org/10.1002/ddr.70180
Research Year
2025
Empagliflozin and memantine combination ameliorates cognitive impairment in scopolamine + heavy metal mixture‑induced Alzheimer’s disease in rats: role of AMPK/mTOR, BDNF, BACE‑1, neuroinflammation, and oxidative stress
Research Abstract
One of the major consequences of diabetes mellitus that has gained attention due to its rising incidence is cognitive impair
ment. Recent research suggested that sodium-glucose cotransporter-2 (SGLT-2) inhibitors can mitigate memory impairment
linked to Alzheimer’s disease and are now being explored for their cognitive benefits. However, their mechanisms were not
thoroughly studied. This research investigates the hypothesis of the neuroprotective effect of empagliflozin administration
against scopolamine-heavy metal mixture (SCO+HMM)-treated Alzheimer’s rat models in comparison with memantine as a
reference drug and the impact of their combination. Yet, the neuroprotective effects of memantine and empagliflozin combina
tion against cognitive impairment have not been previously explored. This study employed adult male albino rats categorized
into five groups. The impact of empagliflozin, memantine, and their concomitant administration on cognitive performance
was assessed in a scopolamine and heavy metal mixture-treated Alzheimer’s disease model in rats. The assessment of rats’
cognitive behavior, memory, and spatial learning was conducted, followed by an evaluation of hippocampal brain-derived
neurotrophic factor (BDNF), beta-secretase (BACE-1), oxidative stress (OS), and inflammatory marker activity. And, a
western blot analysis was conducted to detect phosphorylated 5’ AMP-activated protein kinase (p-AMPK), phosphorylated
mammalian target of rapamycin (p-mTOR), and heme oxygenase-1 (HO-1). Hippocampal and cerebellar histopathology were
thoroughly examined, in addition to the expressions of amyloid β (Aβ). The current data demonstrate the involvement of the
pAMPK/mTOR/HO-1 signaling pathway in empagliflozin neuroprotection against SCO+HMM-induced AD. In addition,
it reduces AD hallmarks (Aβ and BACE1), neuro-inflammation, and oxidative stress sequelae, and enhances neurogenesis
and synaptic density via BDNF. This study proposes that EMPA, especially when co-administered with other conventional
anti-Alzheimer therapy, may be formulated into an innovative therapeutic strategy for the enhancement of cognitive impair
ments associated with neurodegenerative disorders.
Research Date
Research Department
Research Journal
Inflammopharmacology
Research Member
Research Publisher
springer
Research Rank
Q1
Research Vol
33
Research Website
https://doi.org/10.1007/s10787-025-01755-5
Research Year
2025